Pharma-Bio Serv (PBSV) Liabilities and Shareholders Equity (2010 - 2026)

Pharma-Bio Serv (PBSV) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $11.5 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 17.29% year-over-year to $11.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $52.3 million (down 16.46% YoY) and the FY2025 annual result came in at $13.7 million, down 16.2% from the prior year.
• Liabilities and Shareholders Equity fell to $11.5 million in Q2 2026, from $13.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.9 million in Q1 2023 to a low of $11.5 million in Q2 2026.
• A 5-year average of $17.6 million and a median of $18.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity declined 28.91% — and 2023, when it grew 3.74%.
• Tracing PBSV's Liabilities and Shareholders Equity over 5 years: stood at $20.7 million in 2022, then slipped by 3.63% to $19.9 million in 2023, then decreased by 18.14% to $16.3 million in 2024, then dropped by 16.2% to $13.7 million in 2025, then dropped by 15.77% to $11.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $11.5 million (Q2 2026), $13.5 million (Q1 2026), and $13.7 million (Q4 2025), per Business Quant data.